ClinicalTrials.gg
Not yet recruitingNCT07835243Updated Oct 19, 2026

A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of Pegozafermin in Healthy Participants

A Phase 1 interventional study of Pegozafermin in Healthy Volunteers, sponsored by Hoffmann-La Roche. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Basic science

Updated Oct 19, 2026Start date movedGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of a single subcutaneous (SC) dose of pegozafermin administered in the abdomen, thigh, or upper arm in healthy participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,101 studies on the registry; 87 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a (BMI) within the range of 18.5-35.0 kilogram per square meter (kg/m²)
  • Participants in good health, as determined by medical history, physical examination findings, vital signs, (ECG), and clinical laboratory tests at screening and prior to dosing
  • Participants with willingness and ability to comply with all study requirements

Exclusion criteria

Exclusion Criteria:

  • Participants with a history of pancreatitis or gallbladder/biliary disorders (including cholelithiasis or cholecystitis), menstrual abnormalities per investigator judgment, or hypertension
  • Participants with known to pegozafermin or its or history of severe allergic or hypersensitivity reactions that may place the participant at risk
  • Participants with any abnormality of the skin such as tattoo(s) or scarring or SC tissue at or near potential injection sites that may interfere with administration or assessment of the injection
  • Participants with any history of
  • Participants who are pregnant, breastfeeding, or planning to become pregnant during the study or within the timeframe in which is required
  • Participants with a positive result for surface antigen, antibody, or (HIV)-1 or HIV-2 antibodies or p24 antigen at screening
  • Participants with significant alcohol consumption, defined as > 14 units/week for females or > 21 units/week for males
  • Participants with a history of recent (i.e., 6 months) bone trauma, fracture, or surgery or other clinically significant bone-related conditions
  • Participants with poor peripheral venous access

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Group A

    Participants will receive pegozafermin as per the schedule specified in the protocol in the abdomen.

    Drug: Pegozafermin

  • Experimental
    Group B

    Participants will receive pegozafermin as per the schedule specified in the protocol in the thigh.

    Drug: Pegozafermin

  • Experimental
    Group C

    Participants will receive pegozafermin as per the schedule specified in the protocol in the upper arm.

    Drug: Pegozafermin

Interventions

  • Pergozafermin will be administered as specified in the protocol.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Pegozafermin

    Time frame: From predose on Day 1 up to Day 22

  2. Area Under the Serum Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUClast) of Pegozafermin

    Time frame: From predose on Day 1 up to Day 22

  3. Area Under the Serum Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Pegozafermin

    Time frame: From predose on Day 1 up to Day 22

Secondary outcomes

  1. Relative Bioavailability (Frel) of Pegozafermin for Thigh Versus Abdomen

    Time frame: Up to Day 22

  2. Frel of Pegozafermin for Upper Arm Versus Abdomen

    Time frame: Up to Day 22

  3. Time of Maximum Observed Serum Concentration (Tmax) of Pegozafermin

    Time frame: From predose on Day 1 up to Day 22

  4. Terminal Elimination Half-Life (t1/2) of Pegozafermin

    Time frame: From predose on Day 1 up to Day 22

  5. Apparent Systemic Clearance (CL/F) of Pegozafermin

    Time frame: From predose on Day 1 up to Day 22

  6. Apparent Volume of Distribution (Vz/F) of Pegozafermin

    Time frame: From predose on Day 1 up to Day 22

  7. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

    Time frame: Up to approximately 50 days

  8. Number of Participants With Injection Site Reactions (ISRs)

    Time frame: Up to 24 hours post-dose on Day 1

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Mar 2027, 3 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 22, 2026
StartEst.
Nov 5, 2026was Oct 2026
Primary completionEst.
Mar 2, 2027
CompletionEst.
Mar 2, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 7, 2026→Nov 5, 2026
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Start date Oct 7, 2026→Nov 5, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07835243
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 22, 2026
Start date
Nov 5, 2026 (estimated)
Primary completion
Mar 2, 2027 (estimated)
Completion
Mar 2, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Reference Study ID Number: GP46978 https://forpatients.roche.com/ No attachments to email below
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegozafermin

Start the discussion